You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 606 IMpower110: Tertiary lymphoid structures (TLS) and clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with first-line atezolizumab or chemotherapy

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial Completed
606 IMpower110: Tertiary lymphoid structures (TLS) and clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with first-line atezolizumab or chemotherapy

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023698092
Dec 2023201019
Jan 202468015
Feb 202468011
Mar 202494018
Apr 2024132018
May 2024106012
Jun 202496014
Jul 20246207
Aug 202495010
Sep 2024120011
Oct 202494012
Nov 202476012
Dec 20243008
Jan 202586017
Feb 20252407
Mar 2025006
Apr 2025007
May 20250014
Jun 20250013
Total20500323